Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS: In this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma. The primary objectives of phase 1 (dose-escalation cohort) were to assess safety and pharmacokinetics and to identify the dose and schedule for phase 2. In phase 2 (dose-expansion cohort), objectives included the assessment of the overall response (partial response or better), safety, and efficacy of mezigdomide plus dexamethasone at the dose and schedule determined in phase 1. RESULTS: In phase 1, a total of 77 patients were enrolled in the study. The most common dose-limiting toxic effects were neutropenia and febrile neutropenia. On the basis of the phase 1 findings, investigators determined the recommended phase 2 dose of mezigdomide to be 1.0 mg, given once daily in combination with dexamethasone for 21 days, followed by 7 days off, in each 28-day cycle. In phase 2, a total of 101 patients received the dose identified in phase 1 in the same schedule. All patients in the dose-expansion cohort had triple-class-refractory multiple myeloma, 30 patients (30%) had received previous anti-B-cell maturation antigen (anti-BCMA) therapy, and 40 (40%) had plasmacytomas. The most common adverse events, almost all of which proved to be reversible, included neutropenia (in 77% of the patients) and infection (in 65%; grade 3, 29%; grade 4, 6%). No unexpected toxic effects were encountered. An overall response occurred in 41% of the patients (95% confidence interval [CI], 31 to 51), the median duration of response was 7.6 months (95% CI, 5.4 to 9.5; data not mature), and the median progression-free survival was 4.4 months (95% CI, 3.0 to 5.5), with a median follow-up of 7.5 months (range, 0.5 to 21.9). CONCLUSIONS: The all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects. (Funded by Celgene, a Bristol-Myers Squibb Company; CC-92480-MM-001 ClinicalTrials.gov number, NCT03374085; EudraCT number, 2017-001236-19.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationLenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationTeclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationOral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationGandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Morgan, B., Sun, L., Avitahl, N., Andrikopoulos, K., Ikeda, T., Gonzales, E., Wu, P., Neben, S., & Georgopoulos, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.2004 · Cited by 367
Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351
Self-citation
Research works printed but not linked: 22
- 10.1200/EDBK_238527 · DOI
- 10.1097/HS9.0000000000000045 · DOI
- 10.1111/ejh.13046 · DOI
- 10.1038/s41375-019-0435-7 · DOI · Paper page
- 10.1080/10428194.2021.1913143 · DOI
- 10.2217/fon-2021-1090 · DOI
- 10.1016/S2352-3026(22)00290-3 · DOI · Paper page
- 10.1016/j.molimm.2011.03.006 · DOI · Paper page
- 10.1182/blood-2007-07-098202 · DOI · Paper page
- Wong L Jiménez Nuñez MD Bahlis NJ et al. Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480 a novel CELMoD agent in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2020;38:Suppl:8531-8531. abstract (https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8531). · DOI
- Wong L Narla RK Leisten J et al. CC-92480 a novel cereblon E3 ligase modulator is synergistic with dexamethasone bortezomib and daratumumab in multiple myeloma. Blood 2019;134:Suppl 1:1815-1815. abstract (https://ashpublications.org/blood/article/134/Supplement_1/1815/427718/CC-92480-a-Novel-Cereblon-E3-Ligase-Modulator-Is). · doi:10.1182/blood-2019-124345
- 10.1182/blood-2010-10-299487 · DOI · Paper page
- 10.1080/10543400902802409 · doi:10.1080/10543400902802409
- 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
- 10.1007/s11899-020-00568-3 · DOI
- 10.3389/fimmu.2021.720571 · DOI
- 10.1016/j.clml.2015.07.641 · DOI
- 10.1182/blood-2016-01-631200 · DOI · Paper page
- 10.1634/theoncologist.2016-0104 · DOI · Paper page
- 10.1038/s41408-018-0141-0 · DOI · Paper page
- 10.1002/ajh.25134 · DOI
- Richardson PG Sandhu I Oriol A et al. Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 2022;22:Suppl:S33-S33. abstract (https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22)00326-3/fulltext). · doi:10.1016/s2152-2650(22)00326-3
Cited by
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 282
Metadata
- Authors
- Richardson, P. G., Trudel, S., Popat, R., Mateos, M.-V., Vangsted, A. J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R. Z., Arnao, M., Lonial, S., Karanes, C., Pawlyn, C., Kim, K., Oriol, A., Berdeja, J. G., Rodríguez Otero, P., Casas-Avilés, I., Spirli, A., Poon, J., Li, S., Gong, J., Wong, L., Lamba, M., Pierce, D. W., Amatangelo, M., Peluso, T., Maciag, P., Katz, J., Pourdehnad, M., & Bahlis, N. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-14
- Volume
- 389
- Issue
- 11
- Pages
- 1009-1022
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386271388
- Cited by
- 102
- References
- 17
- FWCI
- 18.00
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Bristol-Myers Squibb
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. https://app.cochat.ai/papers/10.1056/nejmoa2303194
- The paper
- Richardson, P. G., Trudel, S., Popat, R., Mateos, M.-V., Vangsted, A. J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R. Z., Arnao, M., Lonial, S., Karanes, C., Pawlyn, C., Kim, K., Oriol, A., Berdeja, J. G., Rodríguez Otero, P., Casas-Avilés, I., Spirli, A., . . . Bahlis, N. J. (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2303194
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.